SIETES :: 92409 citas

Resultados de la búsqueda por FARMACOVIGILANCIA REFINAR BÚSQUEDA

21.

Garattini S, Bertele V. Benefits, benefits, once more benefits... with no risk? Stop overlooking the harms of medicines. Eur J Clin Pharmacol 2018;74:marzo. [Ref.ID 102550]

22.

Casassus B. Risks of reformulation: French patients complain after Merck modifies levothyroxine pills. BMJ 2018;360:k714. [Ref.ID 102544]

23.

Peckham AM, Fairman KA, Sclar DA. All-cause and drug-related medical events associated with overuse of gabapentin and/or opioid medications: a retrospective cohort analysis of a commercially insured US population. Drug Saf 2018;41:213-28. [Ref.ID 102542]

24.

Anónimo. Clarithromycin (Biaxin): Drug safety communication - Potential increased risk of heart problems or death in patients with heart disease. FDA U.S. Food and Drug Administration 2018:22 de febrero. [Ref.ID 102539]

25.

Darrow JJ, Avorn J, Kesselheim AS. The FDA breakthrough-drug designation - Four years of experience. N Engl J Med 2018;378:16 de abril. [Ref.ID 102515]

26.

Lane S, Lynn E, Shakir S. Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012. BMJ Open 2018;8:e019759. [Ref.ID 102510]

27.

Anónimo. Hallucinations and pimavanserin (NUPLAZID), a new kind of drug for psychosis. ISMP Quarter Watch 2018:6. [Ref.ID 102509]

28.

Loftus P. Biogen and Abbvie take Multiple sclerosis drug off market. Wall St J 2018:1. [Ref.ID 102466]

29.

Anónimo. FDA received more reports last year of “rare, frightening side effect” of aflibercept. DIA Daily 2018:4. [Ref.ID 102459]

30.

Anónimo. EMA committee calls for flupirtine to be taken off the market. DIA Daily 2018:7. [Ref.ID 102454]

31.

Anónimo. Soluciones de hidroxietil-almidón: recomendación de suspensión de comercialización. Recomendaciones del Comité para la Evaluación de Riesgos en Farmacovigilancia europeo (PRAC). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2018:15 de enero. [Ref.ID 102444]

32.

Anónimo. Hungarian drugmaker says EMA will decide on ulipristal in first half of this year. DIA Daily 2018:4. [Ref.ID 102443]

33.

Go AS, Singer DE, Toh S, Cheetham TC, Reichman ME, Graham DJ, Southworth MR, Zhang R, Izem R, Goulding MR, Houstoun M, Mott K, Sung SH, Gagne JJ. Outcomes of dabigatran and warfarin for atrial fibrillation in contemporary practice: a retrospective cohort study. Ann Intern Med 2017;167:845-54. [Ref.ID 102196]

34.

Jonker CJ, van den Berg HM, Kwa MSG, Hoes AW, Mol PGM. Registries supporting new drug applications. Pharmacoepidemiol Drug Saf 2017;27:1451-7. [Ref.ID 102187]

35.

Montané E, Arellano AL, Sanz Y, Roca J, Farré M. Drug-related deaths in hospital inpatients: a retrospective cohort study. Br J Clin Pharmacol 2017;84:1. [Ref.ID 102184]

36.

Imatoh T, Sai K, Fukasawa C, Hinomura Y, Nakamura R, Okamoto-Uchida Y, Segawa K, Saito Y. Association between infection and severe drug adverse reactions: an analysis using data from the Japanese Adverse Drug Event Report database. Eur J Clin Pharmacol 2017;73:1643-53. [Ref.ID 102180]

37.

Lin H-F, Liao KF, Chang C-M, Lin CL, Lai S-W. Association of use of selective serotonin reuptake inhibitors with risk of acute pancreatitis: a case-control study in Taiwan. Eur J Clin Pharmacol 2017;73:1615-21. [Ref.ID 102179]

38.

Hamel MB. Speed, safety, and industry funding — From PDUFA I to PDUFA VI. N Engl J Med 2017;377:2278-86. [Ref.ID 102166]

39.

Anónimo. FDA analysis shows many pharmaceutical makers’ post-marketing studies still pending. DIA Daily 2017:11. [Ref.ID 102164]

40.

Anónimo. EMA investigating whether ulipristal acetate can damage the liver. DIA Daily 2017:8. [Ref.ID 102159]